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Pediatric glioblastoma (GBM) can be sub-classified into
several molecular subgroups, including a group defined
by a mutation in histone H3 at position amino acid 27
resulting in the replacement of lysine by methionine
(K27M) [1]. K27M GBMs are located in the midline,
often occur in children, and have been shown to have
worse prognosis than other GBM subgroups, with a
median survival of 6 months [2–5]. The 2016 revision of
the World Health Organization (WHO) Classification of
Tumors of the Central Nervous System now recognizes
“diffuse midline glioma, H3 K27M-mutant” as a distinct
clinic-pathological entity and recommends grading as
Grade 4 [5]. A robust immunohistochemical stain has
been recently developed to specifically detect the K27M
mutation. It can be used to help diagnose these high-
grade tumors, particularly in the setting of a small biopsy
where the amount of tissue is insufficient for molecular
studies [6]. Here we report two patients with midline pilo-
cytic astrocytoma and a glioneuronal tumor, respectively,
harboring a K27M mutation. Our findings show that
K27M mutations may be present in a spectrum of brain
tumors with less aggressive clinical behavior and pro-
longed survival. Our data indicates that the entity of H3
K27M-mutant tumors may represent a spectrum includ-
ing not only diffuse gliomas [5] but also less aggressive
tumors than previously recognized, and that histone H3
K27M mutation should not be used as the sole criterion
for the diagnosis of WHO Grade IV and to imply a dismal
prognosis and aggressive management.
Patient 1 had a past medical history significant for
migraines and presented in July, 2012 after head trauma.
A computed tomography (CT) scan at the time showed
a lesion (Fig. 1a), and was followed by imaging. Three
years later, at 27 years of age, she presented with diffuse
headaches, nausea, and blurry vision. On examination
she was noted to have papilledema, and imaging demon-
strated an expansile enhancing mass lesion in the poster-
ior, right thalamus (Fig. 1b). At the time of surgery, a
well-demarcated border was noted by the neurosurgeon
and good plane was obtained that allowed almost gross
total resection. Macroscopically the tumor was firm and
chalky white suggestive densely gliotic lesion. Micro-
scopically, the tumor showed biphasic pattern with loose
piloid areas (Fig. 1e) and dense areas containing numer-
ous eosinophilic granular bodies (Fig. 1f, arrow) and foci
of microvascular proliferation. Mitotic figures were rare
but the Ki-67 proliferation index was elevated up to
20 % focally (Fig. 1f insert). The tumor was diagnosed as
pilocytic astrocytoma WHO Grade I with elevated Ki-67
proliferation index and the possibility of more aggressive
biological behavior was raised in the report. Immunohis-
tochemical studies showed that the tumor was positive
for K27M mutant protein (Fig. 1h). Copy number analysis
using Illumina 450 k Infinium array showed no detectable
gains or losses (Fig. 1i). The tumor was negative for 3′
BRAF genomic duplication tested by fluorescence in situ
hybridization (FISH) and BRAF V600E by next generation
sequencing. No adjuvant therapy was initiated and the
lesion was followed until 14 months after surgery, when it
showed local recurrence (Fig. 1d). Further resection and
adjuvant therapy were recommended.
Patient 2 was a 10 year-old female with complaints of
headaches and vomiting in June, 2014. Imaging showed
a heterogeneously enhancing midbrain mass (Fig. 2a, c).
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There was marked hydrocephalus due to obstruction.
She underwent resection and the pathology showed a
tumor composed of small round blue cells with high
mitotic activity, expressing synaptophysin (Fig. 2). The
tumor was overall negative for GFAP; however scattered
larger GFAP positive cells were noted (Fig. 2g, insert)
and it was deemed not to be possible to distinguish
whether they represent reactive astrocytes or tumor cells.
Next-generation sequencing of tumor DNA identified
mutations in FGFR1 (N546K), NF1 (E1436fs*4, W2317)
and histone H3F3A (K27M). The K27M mutation was
confirmed in the tissue by immunohistochemistry (Fig. 2h).
Copy number analysis using Illumina 450 k Infinium array
showed no detectable gains or losses (Fig. 2i). Since the
tumor did not fit any WHO entity and due to ambiguous
histological features and molecular analysis, the diagnosis
was reported descriptively as an anaplastic glioneuronal
tumor, WHO grade III. Post-operatively, patient received
proton beam radiation therapy with adjuvant chemother-
apy with temozolomide (90 mg/m2) for 6 weeks. Twenty-
two months after surgery she remains stable with no
recurrence (Fig. 2b, d).
While molecular analysis of tumors adds important
information, it cannot replace histological assessment.
The two patients here were diagnosed with Grade I and
Grade III tumors respectively and were both treated with
surgical resection and the latter also with radiation ther-
apy and adjuvant chemotherapy. Due to the difficulty in
achieving significant resection and high risk of morbid-
ity, patients with midline tumors are often only biopsied
for diagnosis. The K27M immunohistochemical marker
is often used as a diagnostic tool to confirm a midline
high-grade astrocytoma and patients are typically treated
with radiation and chemotherapy. However despite ag-
gressive treatment, the 3-year overall survival (OS) of
patients with K27M GBMs is 5 %. Therefore many con-
sider identifying the K27M mutation as a strong indica-
tion of a high-grade glioma. The cases presented show
that the K27M mutation may be present in less aggressive
“lower grade” gliomas as well as glioneuronal tumors. Our
tumors did not show histological features of diffuse infil-
trating glioma/GBM on imaging or histopathology. One
possible molecular clue arguing against the diagnosis of
GBM in our cases may be a copy number profile without
Fig. 1 The pathologic and radiologic imaging of Patient 1; a axial non-contrast CT 3-years preoperative, showing asymmetry of the posterior
thalami; b axial T1-weighted contrast-enhanced MRI immediately preoperative showing enhancing mass lesion in the right posterior thalamus;
c axial T1-weighted contrast-enhanced MRI 8 months postoperative showing resection of the lesion with no residual tumor d axial T1-weighted
contrast-enhanced MRI 13 months postoperative showing recurrence of the lesion in the right posterior thalamus; e histological evaluation shows
pilocytic astrocytoma with piloid loose areas and f dense areas with eosinophilic granular bodies (f, arrow). The tumor showed focally elevated
Ki-67 up to 10 % (f, insert); The tumor was strongly positive for GFAP (g) and histone H3 K27M (h); i copy number analysis using Illumina 450 k
Infinium array showed no large chromosomal gains or losses of focal amplifications in glioma associated genes (blue labels)
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the typical genomic gains or losses seen in GBM (Figs. 1i
and 2i). Our report highlights a morphological as well as
clinical spectrum of histone H3 K27M mutant tumors.
Our findings imply that, especially in cases where only a
small biopsy is obtained, a sample positive for H3K27M
by immunohistochemistry may be inappropriately diag-
nosed as a high-grade astrocytoma or even GBM and rou-
tinely receive aggressive adjuvant treatment. Therefore,
the presence of a histone H3 K27M mutation should be
evaluated in the context of the histology and other genomic
features to ensure accurate diagnosis. The significance of
histone H3 K27M mutations in tumors that are histologi-
cally not diffuse gliomas is currently unknown; therefore
additional studies are necessary to elucidate the prognostic
impact of this molecular alteration.
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Fig. 2 The pathologic and radiologic imaging of Patient 2; a axial T1-weighted contrast-enhanced MRI immediately preoperative; b axial T1-weighted
contrast-enhanced MRI 22 months postoperative showing no residual tumor; c axial T2 FLAIR MRI immediately preoperative; d axial T2 FLAIR MRI
22 months postoperative showing no residual/recurrent tumor; histological evaluation shows a predominantly small round blue cell tumor tumor (e)
with neuropil islands and rosettes (f); the tumor was strongly positive for neuronal differentiation marker synaptophysin (g). While small round blue
cells were negative for GFAP, rare scattered larger GFAP positive cells were noted (g, insert). Tumor was strongly positive for histone H3 K27M (h);
i copy number analysis using Illumina 450 k Infinium array showed no large chromosomal gains or losses of focal amplifications in glioma associated
genes (blue labels)
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